In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Efficacy and safety of musculoskeletal manipulations in elderly population with musculoskeletal disorders: a systematic review. [PDF]
Bagagiolo D+6 more
europepmc +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Optimization of MALDI Matrices and Their Preparation for the MALDI-TOF MS Analysis of Oligonucleotides. [PDF]
Dietrich S+3 more
europepmc +1 more source
Данъчни Ñ Ñ‚Ð¸Ð¼ÑƒÐ»Ð¸ за Ð½Ð°ÑƒÑ‡Ð½Ð¾Ð¸Ð·Ñ Ð»ÐµÐ´Ð¾Ð²Ð°Ñ‚ÐµÐ»Ñ ÐºÐ°Ñ‚Ð° и развойна Ð´ÐµÐ¹Ð½Ð¾Ñ Ñ‚ в Ñ Ñ‚Ñ€Ð°Ð½Ð¸Ñ‚Ðµ от ОИСРи ЕС [PDF]
ЛР̧Ð Ð ̧Ñ Ð”Ð°Ð ⁄ Ñ Ð ⁄ Ð ⁄ Ра
openalex
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Correction: Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study. [PDF]
Ehrmann D+14 more
europepmc +1 more source
ÐŸÑ€ÐµÐ´Ð¸Ð·Ð²Ð¸ÐºÐ°Ñ‚ÐµÐ»Ñ Ñ‚Ð²Ð° при проектиране, изграждане и ÐµÐºÑ Ð¿Ð»Ð¾Ð°Ñ‚Ð°Ñ†Ð¸Ñ Ð½Ð° Ð¿Ð°Ñ Ð¸Ð²Ð½Ð° Ñ Ð³Ñ€Ð°Ð´Ð° в Ð‘ÑŠÐ»Ð³Ð°Ñ€Ð¸Ñ [PDF]
Ð ̄Ð Ð ⁄ Ñ€ СтР⁄ Ñ Ð ⁄ Ð ⁄ Ð
openalex